Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.30%
#2 Victoria VR Victoria VR +9.12%
#3 Movement Movement +8.40%
#4 COTI COTI +7.33%
#5 DMT-NAT DMT-NAT +6.93%
#6 Palladium Network Palladium Network +4.63%
#7 Prom Prom +4.55%
#8 Test Test +4.07%
#9 GRVT Token GRVT Token +3.80%
#10 Cryptopia Cryptopia +3.74%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rang in Aktien #88
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktienkurs
$47.55
Zuletzt synchronisiert: 2026-08-12
Marktkapitalisierung
$211.25B
Veränderung (1 Tag)
-2.51%
Veränderung (1 Jahr)
-6.99%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)

Kategorie

Healthcare
P/S-Verhältnis für Novo Nordisk A/S (NOVO-B)
P/S-Verhältnis zum February 2026 TTM: 4.47
Laut den neuesten Finanzberichten und dem Aktienkurs von Novo Nordisk A/S beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 4.47. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Novo Nordisk A/S von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
14.97 235.27%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.31 41.28%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.06 58.02%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 4.33%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
4.90 9.81%
US